Showing results (361-370 of 395) with videos related to

Sort By:
Pageof 40
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2021
Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune EvasionFabio Conforti, Laura Pala, Eleonora Pagan, et al.
Lancet (London, England)|July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialAron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
Lancet (London, England)|January 20, 2012
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialJosé Baselga, Ian Bradbury, Holger Eidtmann, et al.
The New England Journal of Medicine|March 5, 2015
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapyHalle C F Moore, Joseph M Unger, Kelly-Anne Phillips, et al.
British Journal of Cancer|January 18, 2020
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.
British Journal of Cancer|April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT TrialsOlivia Pagani, Barbara A Walley, Gini F Fleming, et al.
The Lancet. Oncology|August 19, 2014
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete responseEvandro de Azambuja, Andrew P Holmes, Martine Piccart-Gebhart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 13, 2021
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen SubstudyG Jerusalem, S Farah, A Courtois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2018
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 TrialThomas Ruhstaller, Anita Giobbie-Hurder, Marco Colleoni, et al.
Pageof 40